DepoCyt is a liposomal formulation.
CPX-351 (Vyxeos®) is a 5:1 molar ratio liposomal co-formulation of cytarabine and daunorubicin approved for the treatment of acute myeloid leukemia.
Vasculitis, a part of the cytarabine syndrome, consists of fever, malaise, myalgia, conjunctivitis, arthralgia and a diffuse erythematous maculopapular eruption that occurs from 6–12 hours following the administration of the drug.
